Abstract
We have investigated the effect of exendin-4, a GLP-1 analogue, on somatostatin and insulin secretion in perfused rat pancreas. At constant glucose concentration within the type 2 diabetic range (9 mM), exendin-4 stimulated somatostatin and insulin secretion in a dose-dependent manner. Dose-response curves were sigmoidal (R2 = 0.9954 and R2 = 0.9973, respectively; p < 0.01) and the EC50 was 4.3 nM for somatostatin secretion and 1.4 nM for insulin secretion. Exendin-4 stimulated somatostatin output at low (3.2 mM), normal (5.5 mM) and high (9 mM) glucose concentrations, while the insulinotropic effect of exendin-4 was not found at low glucose levels. On the other hand, exendin-4 potentiated somatostatin and insulin responses to an increase in perfusate glucose levels, and to arginine and carbachol. Finally, the insulinotropic effect of exendin-4 was maintained in the absence of a somatostatin response as induced by cysteamine pretreatment, indicating a direct effect of exendin-4 on the B-cell. In summary, exendin-4 behaves as a general stimulatory agent of both insulin and somatostatin release in the perfused rat pancreas. Given that exendin-4 has also been shown to increase gastric somatostatin secretion, it is tempting to speculate that exendin-4 might behave as a general stimulator of D-cell function in other tissues, a point worthy of further investigation.
Key words
Exendin-4 · Pancreatic somatostatin secretion · Insulin secretion
References
1
Eng J, Kleinman W A, Singh L, Singh G, Raufman J P.
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
J Biol Chem.
1992;
267
7402-7405
2
Göke R, Fehmann H C, Linn T, Schmidt H, Krause M, Eng J, Göke B.
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting B-cells.
J Biol Chem.
1993;
268
19 650-19 655
3
Rodríguez-Gallardo J, Silvestre R A, Egido E M, Marco J.
Insulin secretory pattern induced by exendin-4. Study in the perfused rat pancreas.
Diabetologia.
2000;
43
A138
4
Parkes D G, Pittner R, Jodka C, Smith P, Young A.
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Metabolism.
2001;
50
583-589
5
Egan J M, Clocquet A R, Elahi D.
The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.
J Clin Endocrinol Metab.
2002;
87
1282-1290
6
Tourrel C, Bailbe D, Lacorne M, Meile M J, Kergoat M, Portha B.
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide or exendin-4.
Diabetes.
2002;
51
1443-1452
7
Chepurny O G, Hussain M A, Holz G G.
Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220.
Endocrinology.
2002;
143
2303-2313
8
Silvestre R A, Rodríguez-Gallardo J, Egido E M, Marco J.
Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas.
Eur J Pharmacol.
2003;
469
195-200
9
Gedulin B, Jodka L, Hoyt J.
Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats.
Diabetes.
1999;
48
A199
10
Baron A, Fineman M, Young A, Gaines E, Prickett K.
Synthetic exendin-4 (AC2993) reduces post-prandial glycaemia, glucagon levels and slows gastric emptying in subjects with type 2 diabetes.
Diabetologia.
2000;
43
A190
11
Kolterman O, Gottlieb A, Prickett K, Gaines E, Young A.
Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes.
Diabetes.
2000;
49
A114
12
Parkes D G, Gedulin B, Smith P, Young A.
Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats.
Diabetes.
2001;
50
A313
13
Rodríguez-Gallardo J, Egido E M, Gutiérrez E, Garcia P, Silvestre R A, Marco J.
Evidence for a direct inhibitory effect of exendin-4 on alpha-cell secretion.
Diabetologia.
2002;
45
A214
14
Greig N H, Holloway H W, De Ore K A.
One-daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentration.
Diabetologia.
1999;
42
45-50
15
Young A A, Gedulin B R, Bhavsar S, Bodkin N, Jodka C, Hanse B, Denaro M.
Glucose-lowering and insulin sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Diabetes.
1999;
48
1026-1034
16
Szayna M, Doyle M E, Betkey J A, Holloway H N, Spencer R G, Greig N H, Egan J M.
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
Endocrinology.
2000;
141
1936-1941
17
Tourrel C, Bailbe D, Lacorne M, Meile M J, Kergoat M, Portha B.
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide or exendin-4.
Diabetes.
2002;
51
1443-1452
18
Egan J M, Meneilly G S, Elahi D.
Effects of 1-mo bolus subcutaneaous administration of exendin-4 in type 2 diabetes.
Am J Physiol Endocrinol Metab.
2003;
284
E1072-1079
19
Eissele R, Bothe-Sandfort E, Göke B, Eng J, Arnold R, Koop H.
Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide.
Life Sci.
1994;
55
629-634
20
Silvestre R A, Miralles P, Moreno P, Villanueva M L, Marco J.
Somatostatin, insulin and glucagon secretion by the perfused rat pancreas from the cysteamine-treated rats.
Biochem Biophys Res Commun.
1986;
134
1291-1297
21
Herbert V, Lau K S, Gottlieb C W, Bleicher S J.
Coated charcoal immunoassay of insulin.
J Clin Endocrinol Metab.
1965;
25
1375-1384
22
Kieffer T J, McIntosh C HS, Pederson R A.
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Endocrinology.
1995;
136
3585-3596
23
Mentlein R, Gallwitz B, Schmidt W E.
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
Eur J Biochem.
1993;
214
829-835
24
Parkes D G, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A.
Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1.
Drug Dev Res.
2001;
53
260-267
25
Drucker D J.
Glucagon-like peptides.
Diabetes.
1998;
47
159-169
26
Ørskov C.
Glucagon-like peptide-1, a new hormone of the entero-insular axis.
Diabetologia.
1992;
35
701-711
27
Holz G G, Kühtreiber W M, Habener J F.
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37).
Nature.
1993;
361
362-365
28
Drucker D J, Phillippe J, Mojsov S, Chick W L, Haberner J F.
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.
Proc Natl Acad Sci USA.
1987;
84
3434-3438
29
Blachier F, Mourtada A, Sener A, Malaisse A J.
Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets.
Endocrinology.
1989;
124
134-141
30
Zawalich W S.
Regulation of insulin secretion by phosphoinositide-specific phospholipase V and protein kinase C activation.
Diabetes Review.
1996;
4
160-176
31
Samols E, Stagner J I, Ewart R BL, Marks V.
The order of islet microvascular cellular perfusion is B>A>D in the perfused rat pancreas.
Clin J Invest.
1988;
82
350-353
32
Thorens B, Porret A, Bühler L, Deng S P, Morel P, Widmann C.
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.
Diabetes.
1993;
42
1678-1682
33
Fehmann H C, Haberner J F.
Functional receptors for the insulinotropic hormone glucagon-like peptide-I-(7-37) on a somatostatin secreting cell line.
FEBS Lett.
1991;
279
335-340
34
Gros L, Thorens B, Bataille D, Kervran A.
Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.
Endocrinology.
1993;
133
631-638
35
Göke R, Cole T, Conlon J M.
Characterization of the receptor for glucagon-like peptide-1 (7-36) amide on plasma membranes from rat insulinoma-cells by covalent cross-linking.
J Mol Endocrinol.
1989;
2
93-98
36
Heller R S, Kieffer T J, Habener J F.
Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas.
Diabetes.
1997;
46
785-791
37
Horsck D, Göke R, Eissele R, Michel B, Göke B.
Repriprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islet of rat.
Pancreas.
1997;
14
290-294
38
Thorens N.
Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.
Proc Natl Acad Sci USA.
1992;
89
8641-8645
R. A. Silvestre, Ph. D.
Hospital Universitario Puerta de Hierro and Department of Physiology, Medical School, Universidad Autónoma de Madrid
San Martín de Porres, 4 · 28035 Madrid · Spain
Telefon: +34 (91) 316 22 40, Ext. 5463
Fax: +34 (91) 373 76 67
eMail: rsilvestre.hpth@salud.madrid.org